ScreenerHero

FLNAFilana Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · filanatx.com
0.9610USD-0.54%Mkt Cap: 46.42M $P/E: —

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical t…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap46.42M $
Enterprise Value-37.15M $
Revenue (TTM)—
Gross Profit-15.65M $
Net Income (TTM)-90.97M $
Revenue/Share—
Last Price0.9610 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG1.62
EV/EBITDA3.83
EV/Revenue—
P/S—
P/B0.72
EPS (TTM)-0.85
EPS (Forward)—
52W Range
0.86002% of range4.980
52W High4.980 USD
52W Low0.8600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-122.27%
ROA-76.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.25M $
CapEx (TTM)581.00K $
FCF Margin—
FCF Yield12.61%
Net Debt-82.68M $
Net Debt/EBITDA8.53
Balance Sheet
Debt/Equity—
Current Ratio2.08
Quick Ratio2.06
Book Value/Sh1.317 USD
Cash/Share1.712 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateDec 13, 2012
Pay Date—
Splits
Last Split1:7
Split DateMay 10, 2017
Analyst Consensus
Rating—
Target (Mean)6.500 USD
Upside (mean)+576.4%
Target Range5.000 USD – 8.000 USD
$5.000+576.4% to mean$8.000
# Analysts2
Ownership
Shares Out.48.31M
Float47.32M
Insiders2.05%
Institutions26.72%
Short Interest
Short Ratio18.0d
Short % Float13.65%
Short % Out.13.37%
Shares Short6.46M
Short (prev mo.)6.49M
Technical
SMA 501.080 (-11.0%)
SMA 2001.837 (-47.7%)
Beta-0.69
S&P 52W Chg18.16%
Avg Vol (30d)330.49K
Avg Vol (10d)344.96K
Technical Indicators
RSI (14)45.1
MACD-0.0423
MACD Signal-0.0515
MACD Hist.+0.0092
BB Upper1.040 USD
BB Middle0.9483 USD
BB Lower0.8569 USD
BB Width19.28%
ATR (14)0.0600 USD
Vol Ratio (20d)0.32x